Cullinan Therapeutics (CGEM) Profit After Tax (2020 - 2026)

Cullinan Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$50.6 million for Q1 2026.

• On a quarterly basis, Profit After Tax fell 4.23% year-over-year to -$50.6 million in Q1 2026; TTM through Mar 2026 was -$221.9 million, a 24.17% decrease from a year earlier, with the FY2025 full-year figure at -$219.9 million, down 31.36% from the prior year.
• Profit After Tax was little changed at -$50.6 million in Q1 2026 per CGEM's latest filing, from -$50.7 million in the prior quarter.
• Across five years, Profit After Tax topped out at $174.1 million in Q2 2022 and bottomed at -$70.1 million in Q2 2025.
• The 5-year median for Profit After Tax is -$40.6 million (2024), against an average of -$28.6 million.
• Biggest YoY gain for Profit After Tax was 1158.85% in 2022; the steepest drop was 1008.53% in 2022.
• Year by year, Profit After Tax stood at -$28.8 million in 2022, then climbed by 11.24% to -$25.6 million in 2023, then plunged by 86.39% to -$47.6 million in 2024, then fell by 6.43% to -$50.7 million in 2025, then rose by 0.31% to -$50.6 million in 2026.
• Per Business Quant, the three latest CGEM Profit After Tax figures stand at -$50.6 million (Q1 2026), -$50.7 million (Q4 2025), and -$50.6 million (Q3 2025).